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Primaquine (PQ) is an antimalarial drug with the potential to reduce malaria transmission
due to its capacity to clear mature Plasmodium falciparum gametocytes in the
human host. However, the large-scale roll-out of PQ has to be counterbalanced by
the additional risk of drug-induced hemolysis in individuals suffering from Glucose-
6-phospate dehydrogenase (G6PD) deficiency, a genetic condition determined by
polymorphisms on the X-linked G6PD gene. Most studies on G6PD deficiency and
PQ-associated hemolysis focused on the G6PD A- variant, a combination of the two
single nucleotide changes G202A (rs1050828) and A376G (rs1050829), although other
polymorphisms may play a role. In this study, we tested the association of 20 G6PD
single nucleotide polymorphisms (SNPs) with hemolysis measured seven days after low
single dose of PQ given at the dose of 0.1 mg/kg to 0.75 mg/kg in 957 individuals
from 6 previously published clinical trials investigating the safety and efficacy of this
drug spanning five African countries. After adjusting for inter-study effects, age, gender,
baseline hemoglobin level, PQ dose, and parasitemia at screening, our analysis showed
putative association signals from the common G6PD mutation, A376G [−log10(p-
value) = 2.44] and two less-known SNPs, rs2230037 [−log10(p-value] = 2.60), and
rs28470352 [−log10(p-value) = 2.15]; A376G and rs2230037 were in very strong linkage
disequilibrium with each other (R2 = 0.978). However, when the effects of these SNPs
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were included in the same regression model, the subsequent associations were in
the borderline of statistical significance. In conclusion, whilst a role for the A- variant
is well established, we did not observe an important additional role for other G6PD
polymorphisms in determining post-treatment hemolysis in individuals treated with low
single-dose PQ.
Keywords: genetic association study, clinical trials, malaria, drug safety, hemoglobin
INTRODUCTION
The last two decades of intensive malaria control have
achieved a significant reduction of malaria cases and deaths
and, consequently, several endemic countries were officially
declared in either pre-elimination, elimination, or eradication
stages. One approach to accelerate disease elimination is to
target the sexual and transmission stages of the parasite and,
thereby, block transmission from humans to mosquitoes. The
8-aminoquinoline, Primaquine (PQ), can clear P. falciparum
gametocytes and is typically used as a single-dose treatment. The
drug at larger doses has also the ability to clear Plasmodium vivax
and Plasmodium ovale hypnozoites. However, the biochemical
action of the drug is known to induce transient hemolysis in
treated individuals. The recognition of this side effect led to the
evaluation of the efficacy and safety of treatments based on lower
single doses of PQ for gametocyte clearance in 2011 (Eziefula
et al., 2014). Later, the World Health Organisation (WHO)
revised treatment guidelines and reduced the recommended
PQ dose from 0.75 to 0.25 mg/kg in areas of P. falciparum
elimination and/or high malaria drug resistance (WHO Malaria
Policy Advisory Committee and Secretariat, 2012; World Health
Organization, 2012). After this revision, several randomized
controlled clinical trials and community studies were performed
with the specific aim to assess both the efficacy and the safety of
different PQ drug regimens, including the one based on the new
recommended dose (Dicko et al., 2016; Gonçalves et al., 2016;
Stone et al., 2017; Bastiaens et al., 2018; Chen et al., 2018).
The potential use of PQ-based treatments in large-scale
malaria control and elimination campaigns might pose
an additional risk to individuals with Glucose-6-phospate
dehydrogenase (G6PD) deficiency (Baird and Surjadjaja, 2011;
Awandu et al., 2018; Chen et al., 2018), a common red blood cell
disorder in Africa (Howes et al., 2012). G6PD is a key enzyme
in the pentose phosphate pathway that controls oxidative
damage in erythrocytes. It is encoded by the G6PD gene, which
is located in the telomeric region of the long arm of the X
chromosome (Xq28). Since it results from an X-linked recessive
transmission, G6PD deficiency is more frequent in males but
effects are more difficult to predict in females due to random
X-chromosome inactivation. More than 150 single nucleotide
Abbreviations: BF1, dose-efficacy study from Burkina Faso; BF2, safety study
from Burkina Faso; DBS, dried blood spots; DP, Dihydroartemisinin-piperaquine;
FST, Fluorescence spot test; GAM, safety study from the Gambia; G6PD, Glucose-
6-phospate dehydrogenase; Hb, Hemoglobin; Hb0, Hemoglobin levels at day 0;
Hb7, Hemoglobin levels at day 7; KEN, dose-efficacy study from Kenya; MAL,
safety study from Mali; PQ, Primaquine; RDT, rapid diagnostic test; SNP, Single
Nucleotide Polymorphism; UGD, dose-efficacy study from Uganda.
polymorphisms (SNPs) have been identified in this gene with
different impact on hemolysis and activity of the enzyme (Clarke
et al., 2017). Additionally, there are specific variants that tend
to confer protection against severe malaria-related anemia or
cerebral malaria and these variants are under natural selection
in malaria endemic countries (Maiga et al., 2014; Manjurano
et al., 2015; Clarke et al., 2017; Sepúlveda et al., 2017). In Africa,
the most important genetic markers for G6PD deficiency are
the single nucleotide polymorphism (SNP) rs1050828 (G202A,
or C202T, chrX:154,536,002) and rs1050829 (A376G, or T376C,
chrX:154,535,277) (Rockett et al., 2014). A combination of these
two single nucleotide changes (202A and 376G), also known as
the A- variant, is associated with an 88% loss of G6PD enzyme
activity (Hirono and Beutler, 1988; Beutler et al., 1989), which
decreases the tolerance to 8-aminoquinolines. In principle,
G6PD polymorphisms other than the classical A- variant should
not be associated with significant hemolysis after a single-dose
PQ treatment, but this expectation has never been tested with
data from the field.
To fill in this research gap, we performed a genetic association
analysis of 20 G6PD SNPs using data of 952 individuals from
6 PQ-related clinical trials in Africa: 3 dose-efficacy trials and
3 safety trials. These clinical trials were mostly conducted
in G6PD-normal individuals. The subsequent findings aimed
to contribute to a more accurate pharmacovigilance of PQ-
treatment in the continent.
MATERIALS AND METHODS
Outline of Available PQ Clinical Trials
Data from 957 individuals enrolled in six PQ clinical trials
in Africa were made available for this analysis (Table 1): 330,
107, and 367 individuals from dose-efficacy studies performed
in Burkina Faso (BF1), Kenya (KEN), and Uganda (UGD),
respectively (Eziefula et al., 2014; Gonçalves et al., 2016; Stone
et al., 2017); 77, 50, and 26 individuals from safety studies
conducted in Burkina Faso (BF2), The Gambia (GAM), and Mali
(MAL), respectively (Dicko et al., 2016; Bastiaens et al., 2018).
Briefly, only children were recruited in the BF1, KEN, and
UGD dose-efficacy studies. With respect to the safety studies,
only male adults were enrolled in BF2 and MAL whilst male
adolescents were the majority of the participants from the GAM
study. Only G6PD-normal individuals were considered eligible to
participate in BF1, MAL, and UGD. In contrast, BF2 and GAM
included both deficient and normal individuals with respect to
G6PD enzymatic activity. In KEN, the G6PD status was not
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screened at enrollment. In all safety studies, PQ treatment was
administrated together with a partner drug at day 0 of the trial.
In the dose-efficacy studies, participants received a 3-day course
of dihydroartemisinin-piperaquine (DP) alone or with a single
low dose of PQ (0.25 mg/kg) on the third day of DP treatment
(day 2 of the trial). For additional information about participant’s
recruitment, inclusion/exclusion criteria, and ethics, consult the
original research protocol of each study.
Measurement of Hemoglobin Levels and
Parasitemia
At enrollment (day 0) and on day 7 of the trials, all study
participants had their hemoglobin (Hb) concentration quantified
(g/dL) and had a blood slide prepared to detect malaria parasites
in 100 microscopic fields and quantified against 200 and 500
leukocytes, and then finally translated into parasite counts/µl
under the assumption of 8,000 leukocytes per µl.
Diagnostics of G6PD Deficiency
Participants were screened for G6PD deficiency at enrollment
in all studies with the exception of KEN. The BinaxNOW rapid
diagnostic test (RDT; Alere Inc., Waltham, MA, United States)
was used in BF1 and Beutler’s fluorescence spot test (FST R&D
Diagnostics, Greece) was used in all other studies where G6PD
deficiency was screened.
DNA Extraction and Genotyping
DNA was extracted from dried blood spots (DBS) from UGD,
KEN, and BF1 using the QIAamp DNA Mini Kit (Qiagen,
United Kingdom). DNA was extracted from whole blood samples
from GAM, MAL, and BF2 using the QIAamp DNA Blood Mini
Kit (Qiagen, United Kingdom). All extractions were performed
according to manufacturer’s recommendations.
SNPs were genotyped using either the Kompetitive Allele
Specific PCR (KASP) assay (LGC Genomics, United Kingdom)
or a customized version of the High-throughput Mutation Screen
kit for G6PD (Diacurate Inc., China). The KASP assay (Panel
1: GAM and BF1 and Panels 2: BF2, Supplementary Table 1)
contains two allele-specific forward primers, one common
reverse primer specific for each SNP, 0.8 µL of genomic DNA
suspension and 0.8 µL 2 × KASP reaction mix. The High-
throughput Mutation Screen kit for G6PD consists of a multiplex
extension and ligation-based probe amplification directly from
DBS and was performed in China by Diacurate Incorporated.
The customized assay interrogates 23 SNPs (Panel 3: KEN, MAL,
and UGD, Supplementary Table 1). Following completion of the
PCR, each sample was assigned a genotype based on cluster plot
analysis of raw data using LGC’s proprietary Kraken software.
Genetic Data and Quality Controls
To ensure high quality SNP data, one needs to perform routine
quality checks for genetic association studies (Grabowska et al.,
2020). In this regard, we excluded all SNPs from the analysis
if these SNPs were monomorphic (three SNPs), had a minor
allele frequency <5% (seven SNPs), had a heterozygous frequency
>2% on males (one SNP), had a strong deviation from the
Hardy-Weinberg equilibrium on females (two SNPs; p < 0.001;
Chi-square goodness-of-fit tests), and had a frequency of missing
data >10% (thirteen SNPs). After these quality checks, there
was evidence for a total of 20 high-quality SNPs to be used
in the subsequent genetic association analysis. For a matter of
comparison, allelic frequencies of African populations (n = 1,003
alleles in total) were compiled from the 1000 Genome Project as
available in the database dbSNP (Auton et al., 2015). All of these
genetic markers were annotated according to the forward strand
and the reference genome assembly GRCh38.
Genetic Association Analysis
A linear regression approach was applied to study the genetic
association between the selected SNPs and the hemoglobin
level measured on day 7 after PQ treatment. For statistical
convenience, the hemoglobin level was log-transformed so
that the resulting data would follow an approximate Normal
distribution. The statistical assessment of a genetic association
between a particular SNP and the phenotype of interest was
based on the comparison between two nested regression models
using Wilk’s log-likelihood ratio test. The first model was a
non-genetic linear regression model that included the following
covariates: study index, gender, age, presentation parasitemia,
and hemoglobin level, both day on presentation (hereafter
considered as day 0). The second model is a genetic linear
regression that extends the latter by additionally including a
given genetic effect of SNP under analysis. For each SNP, five
different genetic effects were included in the analysis: general
effect (no specific parametric structure on the genotype effects),
dominance/recessive (genotypes including the dominant allele
had the same effect), additive (the effect of an individual
specific allele in the outcome is additive), and heterosis (both
homozygous genotypes have the same effect). To simplify
the presentation of the results, statistical significance for the
association between a given SNP and the outcome was assessed
by the minimum p-value of all the five p-values comparing the
non-genetic model and five genetic models for the SNP under
analysis. To control for multiple testing, the Benjamini-Hochberg
procedure was applied to all the minimum p-values in order
to obtain an overall false discovery rate of 5% (Benjamini and
Hochberg, 1995). This procedure was based on the following
algorithm: (i) order the p-values from the largest to the smallest,
(ii) calculate the largest k that satisfy pk < 0.05/k where pk is the
k-th ordered p-value; (iii) reject the null hypothesis for all ordered
p-values lower than pk. Statistically significant SNPs were then
assessed in terms of their linkage disequilibrium (LD) using the
correlation coefficient R2.
RESULTS
Inter-Study Variations in Hemoglobin
Levels and PQ Treatment Doses
This study encompassed a total of 957 individuals distributed
across six studies with different sample sizes (Table 1). With
respect to PQ treatment, BF1, BF2, and KEN studies compared
a placebo group to another group treated with a PQ dose
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TABLE 1 | Demographics of each PQ safety and dose-efficacy studies.
Characteristics BF1 BF2 GAM KEN MAL UGD
Reference Gonçalves et al., 2016 Bastiaens et al., 2018 Bastiaens et al., 2018 Stone et al., 2017 Dicko et al., 2016 Eziefula et al., 2014
Type of study Dose-efficacy Safety Safety Dose-efficacy Safety Dose-efficacy
Sample size 330 77 50 107 26 367
G6PD status BinaxNOW RDT Beutler’s FST Beutler’s FST N/A Beutler’s FST Beutler’s FST
Males (n,%) 170 (51.5) 77 (100) 50 (100) 59 (55.1) 26 (100) 183 (49.9)
Mean age (range) 7.7 (2-14) 28.8 (18-44) 16.7 (10-40) 9.6 (5-15) 35.3 (18-50) 5.1 (1-10)
Primaquine dose (n,%)
0.00 (placebo) 105 (31.8) 10 (13.0) 0 (0.0) 53 (49.5) 0 (0.0) 74 (20.2)
0.10-0.40 mg/kg 225 (68.2) 67 (87.0) 50 (100.0) 54 (50.5) 5 (19.2) 201 (54.8)
0.41-0.75 mg/kg 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 21 (80.8) 92 (25.1)
Mean parasitemia (range, parasites/µl)
Day 0 5984.5 (0-237986) 373.8 (0-3348) 90.2 (0-2384) 1692.2 (0-31360) 0 (0) 69766.5 (48-518180)
Day 7 0.4 (0-124) 0 (0-0) 0 (0-0) 1.6 (0-40) 0 (0) 0 (0-16)
Mean hemoglobin (range, g/dL)
Day 0 11.5 (6-14.3) 14.2 (11.4-17.5) 13.1 (11-17.2) 12.0 (9.6-14.8) 15.0 (13.3-17.5) 11.2 (8-15.4)
Day 7 11.3 (7.9-15.1) 13.5 (10.22-17.1) 12.5 (9.9-17.5) 12.2 (8.6-14.8) 14.3 (12-16.2) 10.8 (7.4-15.5)
between 0.1 mg/kg and 0.4 mg/kg. The GAM and MAL
studies only included a single treatment group with a 0.1-
0.5 mg/kg PQ dose. The study from Uganda was the only
one encompassing three treatment arms (placebo, 0.1-0.4 mg/kg
and 0.41-0.75 mg/kg). In MAL, only P. falciparum negative
individuals were recruited to the study.
On the day of treatment (day 0), the mean Hb ranged from
11.2 to 15.0 (overall range = 6.0-17.5) g/dL (Table 1). Since the
targeted populations and recruitment strategies differed across
studies (e.g., male adults in MAL study versus male and female
children in UGD study), an inter-study variation on mean (or
median) Hb levels on day 0 was expected (Figure 1A). Another
possible source of inter-study variation on Hb levels on day 0
(Hb0) was related to differences in parasitemia at presentation
(Figure 1B). Hb0 was lower with the higher parasite counts in
the blood (Spearman’s correlation coefficient = −0.37, p < 0.001).
Unsurprisingly, PQ treatment was associated with a drop in
the Hb levels at day 7 (Hb7) in the majority of the individuals
(Figure 1C) with the level of reduction differing by study. The
studies showed substantial heterogeneity in Hb levels, both on
days 0 and 7 after PQ treatment.
When a non-genetic linear regression model was initially
fitted to the data (Supplementary Table 2), there was evidence
for a negative effect of parasitemia, a positive effect of age,
and a positive effect of log-Hb0 on the log-Hb7 coefficient
estimates = −0.033, 0.004, and 0.567, respectively, all p-values
<0.001). In addition, the effects of different studies on log-Hb7
were not statistically significant (p > 0.05) with the exception of
the study from Kenya (coefficient estimate = 0.047, p < 0.001;
Figure 1C). The effect of each PQ dose range was negative on
the Hb levels at day 7 (coefficient estimates = −0.010 and −0.019
for 0.1–0.4 and >0.4 mg/kg, respectively), which suggested
some degree of hemolysis due to PQ treatment itself. However,
these effects referring to PQ dose ranges were not statistically
significant (p-values = 0.195 and 0.112, respectively). Finally, this
initial model including study index, gender, age, parasitemia at
presentation, and Hb0 as covariates could explain 61% of the total
variation observed in the log-Hb7 levels (adjusted R2 = 0.61). We
then investigated whether genetic variation on G6PD locus could
explain the remaining random variation in the outcome.
Analysis of G6PD SNPs
Genetic analysis initiated by assessing the quality of the
genotype data. Twenty out of the 23 initially genotyped
SNPs were considered with high quality and, thus, they
were carried forward to the association study (Supplementary
Table 3). Of note, ten of the selected SNPs were located
within the coding region of the G6PD gene. Two of these
SNPs represented synonymous variants, other two referred to
known missense variants with pathogenic potential (rs1050829
and rs1050828) and the remaining six SNPs were variants
in the intronic regions of the G6PD gene. The other 10
SNPs were located in the flanking regions of G6PD, namely,
in intronic regions of TLK1, RPL10, SNORA70, and IKBKG
genes. Twelve of these SNPs could not be genotyped in the
samples from BF2 due to unavailability of DNA material to
genotype these SNPs.
In male participants, the allele frequency profile substantially
differed from one study to another, specifically, in SNPs located
within or very close to the coding region of G6PD (Table 2
and Figure 2A). The same finding was obtained when the
allele frequencies associated with each study were compared to
those available from the combined 1000 Genome Project for
African populations (Figure 2B and Supplementary Figure 1).
Interestingly, this variation became less obvious in SNPs located
in the respective flanking regions, probably due to a decrease in
linkage with variants within the G6PD locus.
In female participants, the allele frequency profile did not
significantly differ between studies (Figure 2A). Importantly,
the allelic frequency profile was consistent with the one
available from the combined 1000 Genome project for African
populations (Figure 2B).
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FIGURE 1 | Inter-study variation of Hb0 and Hb7. (A) Violin plots of Hb0 per study. (B) Relationship between Hb0 and parasitemia in infected individuals. Note that
the study from Mali is not shown because it only recruited non-infected individuals. (C) Violin plots of the ratio between Hb0 and Hb7.
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TABLE 2 | Frequencies of the reference alleles associated with each of the 20 SNPs located in the G6PD locus defined between 154,326,058 and 154,607,918





Ref > Alt Allele Gender BF1 BF2 GAM KEN MAL UGD 1000G
rs766420 (TKL1) 154,326,058 Intron C > G Male 0.355 N/A 0.440 0.460 0.269 0.330 0.365
Female 0.359 N/A N/A 0.344 N/A 0.361
rs915941 154,398,308 Upstream A > C Male 0.591 N/A 0.480 0.524 0.231 0.554 0.426
(RPL10,SNORA70) transcription variant Female 0.500 N/A N/A 0.562 N/A 0.535
rs915942 154,398,397 Upstream G > A Male 0.526 N/A 0.667 0.607 0.846 0.606 0.588
(RPL10,SNORA70) transcription variant Female 0.635 N/A N/A 0.562 N/A 0.584
rs28470352 (N/A) 154,525,272 N/A T > A Male 0.702 N/A 0.420 0.629 0.231 0.722 0.663
Female 0.650 N/A N/A 0.719 N/A 0.671
rs61042368 (N/A) 154,527,122 N/A G > A Male 0.751 N/A 0.960 0.885 0.926 0.840 0.873
Female 0.834 N/A N/A 0.885 N/A 0.894
rs12389569 (N/A) 154,529,519 N/A G > A Male 0.900 N/A 0.714 0.902 0.808 0.978 0.903
Female 0.886 N/A N/A 0.958 N/A 0.938
rs77214077 154,532,214 Coding G > A Male 0.953 N/A 0.960 0.903 0.923 0.861 0.910
(G6PD) Synonymous Female 0.947 N/A N/A 0.854 N/A 0.902
rs2230037 (G6PD) 154,532,439 Coding, G > A Male 0.674 0.861 0.800 0.661 0.962 0.766 0.714
Synonymous Female 0.667 N/A N/A 0.698 N/A 0.660
rs73573478 154,533,349 Intron G > A Male 0.749 0.987 0.960 0.885 0.962 0.835 0.875
(G6PD) Female 0.833 N/A N/A 0.875 N/A 0.894
rs2515905 (G6PD) 154,533,860 Intron G > A Male 0.888 0.351 0.780 0.839 0.481 0.833 0.827
Female 0.838 N/A N/A 0.833 N/A 0.799
rs2515904 (G6PD) 154,534,556 Intron (pathogenic) G > C Male 0.889 0.377 0.780 0.836 0.462 0.833 0.827
Female 0.838 N/A N/A 0.833 N/A 0.796
rs1050829a,b 154,535,277 Missense variant T > C Male 0.694 0.234 0.420 0.629 0.192 0.722 0.662
(G6PD) Female 0.625 N/A N/A 0.719 N/A 0.668
rs1050828c (G6PD) 154,536,002 Missense variant C > T Male 0.930 1.000 0.804 0.885 0.462 0.887 0.865
Female 0.870 N/A N/A 0.854 N/A 0.872
rs762515 (G6PD) 154,536,313 Intron T > C Male 0.684 0.227 0.420 0.629 0.154 0.695 0.634
Female 0.619 N/A N/A 0.708 N/A 0.655
rs762516 (G6PD) 154,536,448 Intron C > T Male 0.888 0.355 0.780 0.836 0.462 0.833 0.827
Female 0.838 N/A N/A 0.833 N/A 0.799
rs113492957 154,544,847 Intron C/T Male 0.756 N/A 0.960 0.885 0.962 0.846 0.898
(G6PD,IKBKG) Female 0.838 N/A N/A 0.865 N/A 0.894
rs4898389b (N/A) 154,599,376 N/A G > A Male 0.977 N/A 0.900 0.952 0.962 0.897 0.904
Female 0.978 N/A N/A 0.906 N/A 0.935
rs5986877b (N/A) 154,600,008 N/A G > C Male 0.982 N/A 0.960 0.952 0.962 0.892 0.933
Female 0.984 N/A N/A 0.896 N/A 0.935
rs7879049b (N/A) 154,601,444 N/A G > A Male 0.497 N/A 0.800 0.742 0.846 0.594 0.663
Female 0.560 N/A N/A 0.604 N/A 0.614
rs60030796 (N/A) 154,607,918 N/A A > G Male 0.901 N/A 0.960 0.919 0.885 0.914 0.907
Female 0.900 N/A N/A 0.969 N/A 0.938
The reference (Ref) and alternative (Alt) alleles are given in relation to the minus strand. The last column refers to allelic frequency as reported in the combined 1000
genome project (1000G) for African populations.
a T376C or equivalently A376G.
b Triallelic or quadriallelic SNPs according to reference genome assembly GRCh38.
c C202T or equivalently G202A.
The wild type allele of G6PD-deficiency SNP (G202A,
rs1050828) was found at a high frequency in most of the studies.
The respective relative frequency ranged from 46.2% (MAL) to
100% (BF2) in male participants, whilst it was approximately
constant in female participants (from 85.4% in KEN to 87.2%
in UGD). These results are consistent with only recruiting
participants with normal G6PD enzymatic activity in most of
the studies and, therefore, the respective data was expected to be
enriched with wild type alleles of rs1050828.
Association Analysis Between G6PD
SNPs and Hemolysis After PQ Treatment
Since MAL did not include infected individuals, two separate
genetic association analyses related to variation of log-Hb7 were
Frontiers in Genetics | www.frontiersin.org 6 April 2021 | Volume 12 | Article 645688
fgene-12-645688 April 3, 2021 Time: 22:30 # 7
Sepúlveda et al. G6PD Polymorphisms and Primaquine Treatment
conducted adjusting for previous confounders but including or
not parasitemia at screening as an additional covariate. The
strength of association for each SNP was almost indistinguishable
adjusting or not for parasitemia. In particular, both analyses
suggested putative associations of rs28470352, rs2230037, and
rs1050829 (A376G) with log-Hb7 (Figures 3A,B). There was
evidence for a very strong LD between rs2230037 and rs1050829
(R2 = 0.978). In contrast, these SNPs were in weak LD
with rs28470352 (R2 = 0.208 and 0.227, respectively). These
three polymorphisms were then carried forward to the final
stage of the analysis. There was an additional association
between rs1050828 (G202A) with the phenotype that was only
statistically significant adjusting for confounding but excluding
parasitemia (Figure 3A).
The final stage of the association analysis comprised the
assessment of the joint effect of the three detected SNPs on the
phenotype using extended regression models where genetic and
non-genetic effects were contemplated (Table 3). Since there were
no data available for rs28470352 from BF2, two extended models
were fitted to the data including or not the effect of that genetic
marker; these models were denoted hereafter as M1 and M2,
respectively. As a consequence, the estimation of M1 was based
on a smaller sample size (n = 880) due to the exclusion of the data
from that SNP. In contrast, the estimation of M2 was based on the
whole data set (n = 957).
Both M1 and M2 led to estimates for the non-genetic variables
similar to the ones obtained in absence of genetic effects (Table 3).
More importantly, the effects of rs28470352 and rs1050829
were not statistically significant. Positive effects on log-Hb7
were observed for the AA genotype of rs2230037 (coefficient
estimates = 0.020 and 0.018 for M1 and M2, respectively).
When transformed into linear scale, these effects predicted an
increase of 1.02 g/dL in Hb7 when compared to the GG genotype
of rs223037. However, these effects were in the borderline of
statistical significance (p-values = 0.041 and 0.051, respectively).
In conclusion, the effect size and its statistical significance
suggested that these genetic markers appear to have a minor role
in explaining Hb7 in relation to non-genetic factors, such as age,
parasitemia or Hb0.
DISCUSSION
This study aimed to evaluate the effect of genetic polymorphisms
within G6PD locus on hemolysis on individuals treated with
single doses of PQ. The rationale was to provide information
for safety concerns associated with the broader population
delivery of PQ given the potentially high prevalence of G6PD
deficiency in African populations. This was an opportunistic
study, typing G6PD SNPs in retrospective samples collected from
completed efficacy or safety of single dose PQ in which Hb data
were collected and, as such, there is a number of limitations.
Notwithstanding this fact, we identified putative associations of
the common A376G variant in African population and two less-
known SNP with Hb7. However, these G6PD polymorphisms
appear to have minor effects when compared to the strong non-
genetic effects related to age, parasitemia, and Hb0. This finding
is reassuring from the point of drug safety, because it seems
to rule out any specific effect of G6PD variants on hemolysis
other than the PQ effect alone. In addition, it is important to
note that, as described in the original papers, hemolysis was only
transient in the study participants who had normal levels of Hb
at the end of the respective trials. Therefore, the drug could
be considered safe irrespective of the G6PD variation present
in the study participants, as discussed in the original references
(Bastiaens et al., 2018; Chen et al., 2018) and in a safety study
from Tanzania (Mwaiswelo et al., 2016).
As stated above a limitation is that five out of six studies in
our analysis excluded individuals with reduced G6PD enzymatic
activity and, therefore, the deleterious allele A in G202A was
under-represented in the data through selection bias. This
exclusion criterium reduced the probability to detect any putative
association between that SNP and Hb7. Previous associations
with drops in Hb and both G202A and A376G have been shown
in treatment trials with PQ but this was with the higher dose
of 0.75 mg/kg (Shekalaghe et al., 2009, 2010). Interestingly, the
one individual in those studies that had a significant drop in
Hb levels was wild type at both SNPs suggesting involvement
of other genes elsewhere in the genome, which was in part the
motivation for this study.
We addressed further differences between studies by adjusting
for age and gender in our genetic association analysis. In addition,
age and gender could also control for possible confounding on
the dynamics of Hb during treatment and these were assumed
to be independent of other variables analyzed. A study-specific
effect was also included in the linear regression models to capture
latent (genetic) differences between populations and potential
differences in research protocols. Interestingly, all studies but
KEN had similar study-specific effects in the data. This suggests
that the level of hemolysis observed at day 7 was fairly consistent
across studies. These study-specific effects together with the
effects of parasitemia and Hb0 explained more than half of the
variation observed in Hb7 and suggested that the remaining
variation is not explained by the genetic variation in the G6PD
locus. Further variation might be due to further individual
variation in the rate by which the drug is metabolized in the body.
Genetic polymorphisms on CYP2D6 gene, which are known
to influence the rate by which PQ is metabolized in the body
(Gonçalves et al., 2017; Saito et al., 2018), have been associated
with variation in post treatment gametocyte carriage using data
from 8 clinical trials including the ones here analyzed (Pett et al.,
2019), but a high proportion of missing CYP2D6 data precluded
a more integrated genetic association analysis including the joint
effects of G6PD and CYP2D6 allelic variants on hemolysis.
The KEN study was identified as having a higher study-
specific effect than the remaining studies. This study was the
only one where G6PD deficiency status was not determined in
the participants at enrollment (Stone et al., 2017). However, the
frequency of the deleterious allele A associated with G202A was
consistent with the other studies.
Our study comprised a relatively small number of genotyped
SNPs when compared to more than 250 genetic variants already
identified within the G6PD locus (Clarke et al., 2017). Despite
this hypothetical large number of genetic variants in the G6PD
Frontiers in Genetics | www.frontiersin.org 7 April 2021 | Volume 12 | Article 645688
fgene-12-645688 April 3, 2021 Time: 22:30 # 8
Sepúlveda et al. G6PD Polymorphisms and Primaquine Treatment
FIGURE 2 | Inter-study variation with respect to the genetic data. (A) Comparison of genotype frequencies between studies. Statistical significance was determined
by –log10 (p-value) associated with the Pearson’s test for independence in two-way frequency tables. For males and females, the thresholds for statistical
significance were calculated separately and were determined to ensure a false discovery rate (FDR) of 5%. (B) Comparison between allelic frequencies between
studies and 1000 Genome Project data. The reported –log10 (p-value) refers to the minimum p-value of Binomial test for comparing the allelic frequency of a given
SNP in each study assuming the respective allelic frequency of 1000G project data as the one under the null hypothesis (see Table 2).
Frontiers in Genetics | www.frontiersin.org 8 April 2021 | Volume 12 | Article 645688
fgene-12-645688 April 3, 2021 Time: 22:30 # 9
Sepúlveda et al. G6PD Polymorphisms and Primaquine Treatment
FIGURE 3 | Genetic association analysis between log-Hb7 and each SNP adjusting or not for parasitemia at day 0 (A,B, respectively). Statistical significance was
determined by the maximum of −log10 (p-value) associated with the log-likelihood ratio tests when testing different genetic effects of each SNP in a linear regression
model adjusting for age, gender, parasitemia at screening, and log-Hb0. The threshold for statistical significance was determined to ensure a false discovery rate
(FDR) of 5%.
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TABLE 3 | Estimation of the joint genetic models M1 (excluding data from BF2)
and M2 (based on the whole data set) for the association between log-Hb7 and
the best G6PD SNP adjusting or not for parasitemia at day 0 where the alleles A
and B denote the reference and alternative alleles shown in Table 2.
Model M1 Model M2
Predictor Estimate (SE) P-value Estimate (SE) P-value
Intercept 1.021 (0.068) <0.001 1.020 (0.066) <0.001
Study
BF1 (reference) – – – –
BF2 NA (NA) NA −0.015 (0.021) 0.463
GAM −0.019 (0.019) 0.327 −0.014 (0.019) 0.442
KEN 0.047 (0.011) <0.001 0.047 (0.011) <0.001
MAL −0.018 (0.033) 0.577 −0.004 (0.029) 0.903
UGD 0.015 (0.009) 0.100 0.012 (0.009) 0.159
Age (per year) 0.005 (0.001) <0.001 0.004 (0.001) <0.001
PQ dose (mg/kg)
0 – – – –
0.10-0.40 −0.007 (0.008) 0.399 −0.007 (0.008) 0.328
0.41-0.75 −0.016 (0.012) 0.175 −0.017 (0.012) 0.159
Gender
Female (reference) – – – –
Male −0.010 (0.009) 0.261 −0.012 (0.009) 0.193
log-Hb0 0.561 (0.029) <0.001 0.565 (0.027) <0.001
Parasitemia (x 100,000) −0.033 (0.005) <0.001 −0.033 (0.005) <0.001
rs28470352
TT (reference) – – – –
TA −0.003 (0.040) 0.946 – –
AA −0.061 (0.065) 0.353 – –
rs2230037
GG (reference) – – – –
GA 0.007 (0.010) 0.467 0.006 (0.010) 0.506
AA 0.020 (0.010) 0.041 0.018 (0.009) 0.051
rs1050829
TT (reference) – – – –
CT −0.012 (0.040) 0.768 −0.016 (0.010) 0.117
CC 0.051 (0.065) 0.439 −0.011 (0.009) 0.208
locus, many of catalogued SNPs have too-low minor allele or they
are only present in non-African populations. In this regard, the
evaluated SNPs were considered the most informative in terms
of allele frequency in African populations. As a limitation, half
of the evaluated SNPs were outside the G6PD coding region.
Given this scenario, it is then possible that additional association
signals could derived from rare genetic variants located in this
locus. However, these association signals could only be detected
in studies with large sample sizes, as illustrated by the UK10k
consortium (Walter et al., 2015) and the study of genetic variants
related to blood pressure (Surendran et al., 2020). It is worth
noting that the telomeric location of the G6PD gene on the X
chromosome imposes serious limitations in terms of the assay
costs and scalability to a large number of samples and SNP
under analysis, as illustrated in the most comprehensive genetic
study of G6PD variation conducted so far (Clarke et al., 2017).
From an initial number of more than 250 SNPs, the authors
considered the study only feasible in a benchmark set of 65
SNPs located in a 560 kb region spanning the G6PD locus itself
and part of the overlapping IKBKB gene (encoding Inhibitor of
Kappa Light Polypeptide Gene Enhancer in B-Cells). Since our
study comprised the analysis of retrospective data, there was a
limitation to the number of SNP under analysis. In this regard,
we considered these SNPs to be a good representation of this
reference set, because only three SNPs were discarded after our
quality control checks.
Despite the inherent limitations in attempting to combine
different studies, all used a single dose of PQ, had measures
of Hb7 after the initiation of treatment and the same core
group of G6PD-associated SNPs were tested. Consistent with
previous reports we reported borderline associations of specific
G6PD SNPs with mild transient hemolysis. This provides further
evidence that single, low dose PQ can be deployed in larger
population studies.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusion of this article will be
made available by the authors, without undue reservation.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by the Ethics Committee of the Faculty of Medicine,
Pharmacy, and Dentistry, University of Science, Techniques
and Technologies of Bamako, and the Committee on Human
Research at the University of California, San Francisco (studies
in Mali); the Comité d’Ethique pour la Recherche en Santé,
Ministère de la Santé du Burkina Faso, and the Comité Technique
d’Examen des Demandes d’Autorisation d’Essais Cliniques,
Ministère de la Santé du Burkina Faso (studies in Burkina Faso);
the Gambia Government/MRC Joint Ethics Committee (studies
in the Gambia); the Makerere University School of Medicine
Research Ethics Committee and the Uganda National Council of
Science and Technology (study in Uganda); the Kenya Medical
Research Institute Ethics Review Committee (study in Kenya);
and the Interventions Research Ethics Committee of the London
School of Hygiene and Tropical Medicine (all studies). Written
informed consent to participate in this study was provided by the
participants’ legal guardian/next of kin.
AUTHOR CONTRIBUTIONS
TB and CD conceived the research. JC, LM, GB, AT, JO, SAC,
BG, MA, AO, EB, GS, IN, KL, SS, AD, Ud’A, IC, AE, RG, TB,
and CD were involved in data collection, lab processing, and data
interpretation of the clinical trials analyzed. NS, LG, JC, TC, and
SC decided the list of SNPs to be genotyped. LG, JC, and SC
organized and performed the SNP genotyping. NS performed
the statistical analysis. NS, LG, and CD wrote the manuscript.
All authors have revised, read, and approved the final version
of the manuscript.
Frontiers in Genetics | www.frontiersin.org 10 April 2021 | Volume 12 | Article 645688
fgene-12-645688 April 3, 2021 Time: 22:30 # 11
Sepúlveda et al. G6PD Polymorphisms and Primaquine Treatment
FUNDING
TC was funded by the Medical Research Council UK (Grant
no. MR/M01360X/1, MR/N010469/1, MR/R025576/1, and
MR/R020973/1) and BBSRC UK (Grant no. BB/R013063/1).
SC was funded by Bloomsbury SET, Medical Research Council
UK (MR/M01360X/1, MR/R025576/1, and MR/R020973/1), and
BBSRC UK (Grant no. BB/R013063/1). AE received funding
from a Wellcome Clinical Fellowship (090558). LG, BG, and
CD were funded from the Bill & Melinda Gates Foundation
for the Primaquine supplement to AFIRM (OPP1034789). NS
was partially funded by FCT – Fundação para a Ciência e a
Tecnologia, Portugal (Ref. Grant: UIDB/00006/2020).
SUPPLEMENTARY MATERIAL




Auton, A., Abecasis, G. R., Altshuler, D. M., Durbin, R. M., Bentley, D. R.,
Chakravarti, A., et al. (2015). A global reference for human genetic variation.
Nature 526, 68–74. doi: 10.1038/nature15393
Awandu, S. S., Raman, J., Makhanthisa, T. I., Kruger, P., Frean, J., Bousema, T.,
et al. (2018). Understanding human genetic factors influencing primaquine
safety and efficacy to guide primaquine roll-out in a pre-elimination
setting in southern Africa. Malar. J. 17:120. doi: 10.1186/s12936-018-
2271-z
Baird, J. K., and Surjadjaja, C. (2011). Consideration of ethics in primaquine
therapy against malaria transmission. Trends Parasitol. 27, 11–16. doi: 10.1016/
j.pt.2010.08.005
Bastiaens, G. J. H., Tiono, A. B., Okebe, J., Pett, H. E., Coulibaly, S. A., Gonçalves,
B. P., et al. (2018). Safety of single low-dose primaquine in glucose-6-phosphate
dehydrogenase deficient falciparum-infected African males: two open-label,
randomized, safety trials. PLoS One 13:e0190272. doi: 10.1371/journal.pone.
0190272
Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate: a
practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat.
Methodol. 57, 289–300.
Beutler, E., Kuhl, W., Vives-Corrons, J., and Prchal, J. (1989). Molecular
heterogeneity of glucose-6-phosphate dehydrogenase A-. Blood 74, 2550–2555.
doi: 10.1182/blood.v74.7.2550.2550
Chen, I., Diawara, H., Mahamar, A., Sanogo, K., Keita, S., Kone, D., et al. (2018).
Safety of single-dose primaquine in G6PD-deficient and G6PD-normal males
in mali without malaria: an open-label, phase 1, dose-adjustment trial. J. Infect.
Dis. 217, 1298–1308. doi: 10.1093/infdis/jiy014
Clarke, G. M., Rockett, K., Kivinen, K., Hubbart, C., Jeffreys, A. E., Rowlands, K.,
et al. (2017). Characterisation of the opposing effects of G6PD deficiency on
cerebral malaria and severe malarial anaemia. Elife 6:e15085.
Dicko, A., Brown, J. M., Diawara, H., Baber, I., Mahamar, A., Soumare,
H. M., et al. (2016). Primaquine to reduce transmission of Plasmodium
falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised
phase 2 trial. Lancet Infect. Dis. 16, 674–684. doi: 10.1016/S1473-3099(15)
00479-X
Eziefula, A. C., Bousema, T., Yeung, S., Kamya, M., Owaraganise, A., Gabagaya, G.,
et al. (2014). Single dose primaquine for clearance of Plasmodium falciparum
gametocytes in children with uncomplicated malaria in Uganda: a randomised,
controlled, double-blind, dose-ranging trial. Lancet Infect. Dis. 14, 130–139.
doi: 10.1016/S1473-3099(13)70268-8
Gonçalves, B. P., Pett, H., Tiono, A. B., Murry, D., Sirima, S. B., Niemi, M.,
et al. (2017). Age, weight, and CYP2D6 genotype are major determinants
of primaquine pharmacokinetics in African children. Antimicrob. Agents
Chemother. 61:e02590-16. doi: 10.1128/AAC.02590-16
Gonçalves, B. P., Tiono, A. B., Ouédraogo, A., Guelbéogo, W. M., Bradley, J., Nebie,
I., et al. (2016). Single low dose primaquine to reduce gametocyte carriage and
Plasmodium falciparum transmission after artemetherlumefantrine in children
with asymptomatic infection: a randomised, double-blind, placebo-controlled
trial. BMC Med. 14:40. doi: 10.1186/s12916-016-0581-y
Grabowska, A. D., Lacerda, E. M., Nacul, L., and Sepúlveda, N. (2020).
Review of the quality control checks performed by current genome-wide
and targeted-genome association studies on myalgic encephalomyelitis/chronic
fatigue syndrome. Front. Pediatr. 8:293. doi: 10.3389/fped.2020.00293
Hirono, A., and Beutler, E. (1988). Molecular cloning and nucleotide sequence of
cDNA for human glucose-6-phosphate dehydrogenase variant A(-). Proc. Natl.
Acad. Sci. U. S. A. 85, 3951–3954. doi: 10.1073/pnas.85.11.3951
Howes, R. E., Piel, F. B., Patil, A. P., Nyangiri, O. A., Gething, P. W., Dewi, M.,
et al. (2012). G6PD deficiency prevalence and estimates of affected populations
in malaria endemic countries: a geostatistical model-based map. PLoS Med.
9:e1001339. doi: 10.1371/journal.pmed.1001339
Maiga, B., Dolo, A., Campino, S., Sepulveda, N., Corran, P., Rockett, K. A., et al.
(2014). Glucose-6-phosphate dehydrogenase polymorphisms and susceptibility
to mild malaria in Dogon and Fulani, Mali. Malar. J. 13:270. doi: 10.1186/1475-
2875-13-270
Manjurano, A., Sepulveda, N., Nadjm, B., Mtove, G., Wangai, H., Maxwell, C.,
et al. (2015). African glucose-6-phosphate dehydrogenase alleles associated with
protection from severe malaria in heterozygous females in Tanzania. PLoS
Genet. 11:e1004960. doi: 10.1371/journal.pgen.1004960
Mwaiswelo, R., Ngasala, B. E., Jovel, I., Gosling, R., Premji, Z., Poirot, E., et al.
(2016). Safety of a single low-dose of primaquine in addition to standard
artemether-lumefantrine regimen for treatment of acute uncomplicated
Plasmodium falciparum malaria in Tanzania. Malar. J. 15:316. doi: 10.1186/
s12936-016-1341-3
Pett, H., Bradley, J., Okebe, J., Dicko, A., Tiono, A. B., Gonçalves, B. P., et al. (2019).
CYP2D6 polymorphisms and the safety and gametocytocidal activity of single-
dose primaquine for Plasmodium falciparum. Antimicrob. Agents Chemother.
63:e00538-19. doi: 10.1128/AAC.00538-19
Rockett, K. A., Clarke, G. M., Fitzpatrick, K., Hubbart, C., Jeffreys, A. E., Rowlands,
K., et al. (2014). Reappraisal of known malaria resistance loci in a large
multicenter study. Nat. Genet. 46, 1197–1204.
Saito, T., Gutiérrez Rico, E. M., Kikuchi, A., Kaneko, A., Kumondai, M., Akai,
F., et al. (2018). Functional characterization of 50 CYP2D6 allelic variants
by assessing primaquine 5-hydroxylation. Drug Metab. Pharmacokinet. 33,
250–257. doi: 10.1016/j.dmpk.2018.08.004
Sepúlveda, N., Manjurano, A., Campino, S. G., Lemnge, M., Lusingu, J., Olomi,
R., et al. (2017). Malaria host candidate genes validated by association with
current, recent, and historical measures of transmission intensity. J. Infect. Dis.
216, 45–54.
Shekalaghe, S., Alifrangis, M., Mwanziva, C., Enevold, A., Mwakalinga, S., Mkali,
H., et al. (2009). Low density parasitaemia, red blood cell polymorphisms
and Plasmodium falciparum specific immune responses in a low endemic
area in northern Tanzania. BMC Infect. Dis. 9:69. doi: 10.1186/1471-23
34-9-69
Shekalaghe, S. A., ter Braak, R., Daou, M., Kavishe, R., Van den Bijllaardt, W.,
Van den Bosch, S., et al. (2010). In Tanzania, hemolysis after a single dose of
primaquine coadministered with an artemisinin is not restricted to glucose-6-
phosphate dehydrogenase-deficient (G6PD A-) individuals. Antimicrob. Agents
Chemother. 54, 1762–1768. doi: 10.1128/AAC.01135-09
Stone, W., Sawa, P., Lanke, K., Rijpma, S., Oriango, R., Nyaurah, M., et al.
(2017). A molecular assay to quantify male and female Plasmodium falciparum
gametocytes: results from 2 randomized controlled trials using primaquine
for gametocyte clearance. J. Infect. Dis. 216, 457–467. doi: 10.1093/infdis/
jix237
Frontiers in Genetics | www.frontiersin.org 11 April 2021 | Volume 12 | Article 645688
fgene-12-645688 April 3, 2021 Time: 22:30 # 12
Sepúlveda et al. G6PD Polymorphisms and Primaquine Treatment
Surendran, P., Feofanova, E. V., Lahrouchi, N., Ntalla, I., Karthikeyan, S., Cook,
J., et al. (2020). Discovery of rare variants associated with blood pressure
regulation through meta-analysis of 1.3 million individuals. Nat. Genet. 52,
1314–1332. doi: 10.1038/s41588-020-00713-x
Walter, K., Min, J. L., Huang, J., Crooks, L., Memari, Y., McCarthy, S., et al. (2015).
The UK10K project identifies rare variants in health and disease. Nature 526,
82–89. doi: 10.1038/nature14962
WHO Malaria Policy Advisory Committee and Secretariat (2012). Malaria
Policy Advisory Committee to the WHO: conclusions and recommendations
of September 2012 meeting. Malar. J. 11:424. doi: 10.1186/1475-2875-
11-424
World Health Organization (2012). Updated WHO Policy Recommendation: Single
Dose Primaquine as a Gametocytocide in Plasmodium Falciparum Malaria.
Available online at: https://www.who.int/malaria/publications/atoz/who_pq_
policy_recommendation/en/ (accessed November 29, 2020)
Conflict of Interest: JC and LM were employed by the company LGC Genomics.
The remaining authors declare that the research was conducted in the absence of
any commercial and financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2021 Sepúlveda, Grignard, Curry, Mahey, Bastiaens, Tiono, Okebe,
Coulibaly, Gonçalves, Affara, Ouédraogo, Bougouma, Sanou, Nébié, Lanke, Sirima,
Dicko, d’Alessandro, Clark, Campino, Chen, Eziefula, Gosling, Bousema and
Drakeley. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Genetics | www.frontiersin.org 12 April 2021 | Volume 12 | Article 645688
